Tempus AI’s Post

Cancer-causing mutations impact signalling pathways and affect apoptosis, autophagy, cell migration, angiogenesis and cell division cycle. GeneTex, Inc. released a poster highlighting selected cancer signalling pathways. Download posters now: https://lnkd.in/g49GTQhM All products listed on this site are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use

We look forward to disclosing first-in-patient clinical data at the coming ASCO. CS5001 is an antibody-drug conjugate (ADC) targeting ROR1 (receptor tyrosine kinase-like orphan receptor 1). CS5001 is uniquely designed using LCB's proprietary tumor-cleavable linker and pyrrolobenzodiazepine (PBD) prodrug. Only after entering the tumor cells, are the linker and prodrug cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. This double safety measure effectively reduces toxicity associated with traditional PBD payloads, leading to a better safety profile and therapeutic window. Read more here: https://lnkd.in/giPWhGjN

Nature Reviews Drug Discovery at Springer Nature Group and Nature Portfolio highlights the latest publication of our co-founders Luis Alvarez-Vallina and Belén Blanco Durango on STAb Technology for the treatment of #multiplemyeloma. This research highlight recaps the most relevant results obtained in the preclinical study showing the superiority of STAb-TBCMA compared to CAR T cells against the same target. As our co-founder underscores in the research highlight: “In this strategy, T cell recruitment is not restricted to engineered T cells (…). The polyclonal recruitment by TCEs of both engineered and unmodified bystander T cells, present at the tumour site, lead to a significant boost in antitumour T cell responses”. We are eager to continue the development of our product STAb-TBCMA and the development of our #STAbTechnology for other cancer types. You can access the Research Highlight here: https://lnkd.in/duXK4BJE For the original paper on STAb-TBCMA: https://lnkd.in/e38ugSjW   #immunotherapy #cancertherapeutics #multiplemyeloma #immunooncology #celltherapy

Yesterday was a monumental day for #cancer patients and for Strand Therapeutics. STX-001, the first-ever programmable mRNA therapy, entered the clinic in a Phase 1 trial for solid tumors. Programmable mRNA therapies are based on groundbreaking technology with the potential to transform the treatment of cancer and other diseases. To learn more, read on! (And if your at #ASCO, check out Strand's poster.) #mRNA #ASCO2024 #ASC024

1. Dr. Karen Tkach Tuzman of BioCentury Inc. provided an elegant analysis of tumor cell surface targets presented at AACR24 and ASCO24. Among these, five neuronal proteins stood out to me. 2. The five mentioned targets—SEZ6, EPHA5, CNTN4, SLITRK6, and NPTXR—are aberrantly expressed in solid tumors, while in neurons, these targets promote axon and dendrite growth and synapse formation. 3. Dr. Tuzman highlighted a key question for this target class: whether they will exhibit neurotoxicity. She noted that the low blood-brain barrier (BBB) penetration of antibody-based therapies, particularly ADCs, could mitigate this risk. 4. The Destiny-Breast03 study shows that specific ADCs can effectively treat patients with brain metastases. However, since the study primarily enrolled patients with stable metastases post-local treatment, the efficacy in patients with active metastases remains uncertain. 5. The reason for T-Dxd's efficacy in patients with brain metastases is unclear. The integrity of the BBB can change due to pathological conditions like inflammatory diseases (e.g., multiple sclerosis) and primary or secondary brain tumors. However, the blood-tumor barrier (BTB), formed when tumors disrupt BBB integrity, shows highly heterogeneous permeability within tumors and is characterized by active efflux of molecules. 6. The BBB and BTB in patients with brain metastases from primary cancers or brain tumors can be very heterogeneous. Therefore, the neurotoxicity of ADC drugs targeting proteins expressed in neurons warrants careful consideration. Ref: https://lnkd.in/g-UfiDiP

Enroll in Champions' 1st Autologous TumorGraft3D Co-Culture Screen - featuring 13 unique, clinically relevant TumorGraft3D models with matched TILs selected by experts to assess your immuno-oncology agents. Champions’ autologous TumorGraft3D co-culture platform leverages a matrix-free assay, using indication-specific proprietary media to allow for model formation and retention of patients’ key molecular and phenotypical features, with matched TILs added in culture after model formation. Autologous TumorGraft3D Co-Culture is the ideal ex vivo platform to: ✔️ Measure immuno-oncology agent efficacy and lymphocyte recruiting/activating effects, ✔️ Unravel the complexities of tumor biology and the crucial interactions within the tumor microenvironment, ✔️ Evaluate synergistic combination therapies to advance your drug development through data-driven decisions. Explore Champions' Autologous TumorGraft3D Co-Culture Screen, enrolling until May 31: https://hubs.li/Q02rLnkf0 #screen #oncologyresearch #oncology #organoid #cancerresearch #cancer #personalizedmedicine #tumorgraft3d #immunooncology #IO #tumorinfiltratinglimphocytes #TIL #autologous #coculture #AACR24

💡Poster Presentation Today! Don't miss Erin Trachet presenting on how flow cytometry is utilized to evaluate cell cycle arrest. https://hubs.li/Q02s1Ht90 Session: Cell Cycle, Transcription Regulation, and Anticancer Drug Action, Poster Section 21 Poster Board Number 7 Key Takeaways: Flow cytometry is a key tool in cancer research, pivotal for assessing the effects of drugs on cell cycle regulation and for informing potential combination therapies. In vivo and in vitro studies using cell cycle modulators like Palbociclib and DNA damaging agents like Cisplatin have shown modest tumor growth inhibition, underscoring their therapeutic potential. While Palbociclib treatment induced G1 phase arrest, Cisplatin, Thymidine, and Nocodazole resulted in G2 phase arrest, highlighting the need for further research to optimize dosing and improve outcomes.

New natural products from Salvia demonstrate promising potential in cancer therapy. These tanshinolic compounds, particularly (±)-13e, exhibit significant Ah receptor inhibitory activity, resulting in the inhibition of tumor cell proliferation and a boost in immune responses, promoting INF-γ secretion in CD8+ T cells. https://lnkd.in/ggtX4NAn

One of the key topic areas at #WorldCBandCDx includes CDx in ADCs. #Geneexpression will play a critical role in the development of ADC therapies, the next generation of immunotherapies that hold huge potential for cancer patients. Understanding #transcriptomics data to reveal tumor heterogeneity, immune responses and biomarkers discovery are diverse areas where latest #cfRNA NGS technologies can be utilized to accelerate ADC drug development. Sysmex Inostics’ broad portfolio of comprehensive cfRNA plus cfDNA panels can provide unique solutions to your liquid biopsy needs for ADCs. Come speak with our experts to learn how we can expedite your ADC clinical trials! https://hubs.la/Q02L8G6-0 #cellfreeDNA #ADCs #ADCclinicaltrial

When it comes to tumor surface targets for modalities like ADCs, we're always hearing about the usual suspects: HER2, TROP2, Claudin18.2. Using #ASCO24, #AACR24 and BioCentury Inc.'s BCIQ database, we shine a light on emerging targets off that beaten path, and see a trend toward targeting neuronal regulators hijacked by cancer. Were any of these targets on your radar? https://lnkd.in/gwykTWAi